Enhancing Glaucoma Outcomes With Preserflo Microshunt : 2 Center Experience
Published 2025 - 43rd Congress of the ESCRS
Reference: PO679 | Type: Free paper | DOI: 10.82333/epk6-zq93
Authors: Rosa Boccia* 1 , Michele Lanza 1 , Salvatore Ambrosio 1 , Luigi Serra 1 , Italo Fattore 1 , Francesco Abbate 1 , Teresa Cangiano 1 , Francesca Agricola 1 , Francesca Simonelli 1
1Dipartimento Multidisciplinare di Specialità Mediche, Chirurgiche ed Odontoiatriche,Università della Campania Luigi Vanvitelli,Napoli,Italy
Purpose
The Preserfo microshunt is a minimally invasive infiltaration device designed to lower intraocular pressure in glaucoma patients. This study evaluates its efficacy, safety and impact on medication burden in a two center cohort
Setting
the study was conducted at NMC royal hospital and al zahra dubai hospital , using 0.4 mg/ml MMC with topical applicaiton fotr 3 mins
Methods
A retrospective analsysis was conducted on 25 eyes from 23 patients who underwent PRESERFLO microshunt implantation for POAG or secondary glaucoma.
IOP reduction, medication use, surgical success rate, post operative complications were assessed over 12-month follow up period Surgical success was defined as an IOP reduction of > 20% from baseline without additional surgical intervention
Results
The mean preoperative IOP was 24.8 ± 4.1 mmHg, which significantly decreased to 13.6 ± 3.0 mmHg at 12 months postoperatively (p < 0.001). The number of glaucoma medications was reduced from a mean of 3.1 ± 1.0 preoperatively to 1.0 ± 0.8 at the final follow-up. Complete surgical success was achieved in 76% of cases, while 88% achieved qualified success (with or without medication). Postoperative complications included transient hypotony in 12% of cases, bleb-related complications in 8%, and a need for needling in 10%. No cases of endophthalmitis, choroidal detachment, or device failure were observed.
Conclusions
The PRESERFLO MicroShunt significantly reduced IOP and medication dependence with a favorable safety profile in this two -center experience. These findings support its role as an effective alternative to traditional filtration surgery for glaucoma, though further long-term studies are needed to assess its durability